Coagulation Factor Deficiency Market Size is valued at USD 5.50 Bn in 2023 and is predicted to reach USD 9.60 Bn by the year 2031 at a 7.36% CAGR during the forecast period for 2024-2031.
Coagulation factor deficiency refers to a medical disorder characterized by an inadequate or malfunctioning of coagulation factors, which are proteins responsible for blood clotting. This can result in hemorrhagic diseases, manifesting as signs such as facile ecchymosis, protracted bleeding following traumas, and excessive menstrual bleeding. Treatment entails the substitution of the missing factor or the use of medicines to induce clotting. There has been an increase in government funding, along with efforts from governmental and private organizations, to promote rising awareness and understanding of this disease. Furthermore, advancements in medical technology, genetic counselling, and the growing adoption of early screening methods are anticipated to accelerate market growth.
Additionally, to further stimulate the demand for factor VII treatment products, it is essential to conduct awareness campaigns and educational programs targeting both healthcare professionals and patients. These initiatives can lead to earlier detection and treatment of bleeding disorders, ultimately enhancing the quality of care for affected individuals. Notably, there is substantial variation in the prevalence, diagnosis, and treatment approaches for coagulation factor deficiencies across different regions and countries. This diversity can present challenges in developing standardized global treatment strategies.
Competitive Landscape
Some Major Key Players In The Coagulation Factor Deficiency Market:
- Pfizer Inc
- Grifols
- Biogen
- Octapharma
- Baxter
- Bayer
- CSL Behring
- Novo Nordisk
- Greencross
- Kedrion
- BPL
- Hualan Bio
- RAAS
- Ferring B.V.,
- Hoffmann-La Roche AG,
- Others
Market Segmentation:
The coagulation factor deficiency market is segmented on the basis of deficiency type, product and end users. Based on deficiency type, the coagulation factor deficiency market is segmented as Haemophilia A, Haemophilia B, von Willebrand disease, factor xi deficiency, factor xiii deficiency and others. By product, the Coagulation Factor Deficiency market is segmented into recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, biologics, desmopressin and others. By product, the coagulation factor deficiency market is segmented into hospitals, clinics, home care and others.
Based On End Users, The Hospital Segment Is Accounted As A Major Contributor To The Coagulation Factor Deficiency Market.
The hospital category is expected to record a major share of the global coagulation factor deficiency market in 2024. Increasing hospital demand in the coagulation factor deficiency market suggests that hospitals are experiencing a growing need for resources and services to address coagulation factor deficiencies, reflecting a rising trend in healthcare demands associated with this medical condition. Hospitals play a crucial role in diagnosing and treating patients with such conditions, so their demand for relevant resources is vital. This indicates the market associated with products and services related to coagulation factor deficiencies. This market includes items like factor VII treatment products, diagnostic tools, medications, and other healthcare services directed at individuals with coagulation factor deficiencies.
The Biologics Segment Witnessed Growth At A Rapid Rate.
The biologics segment is projected to grow at a rapid rate in the global coagulation factor deficiency market. Biologics are typically derived from living organisms and are used for various medical purposes, including the treatment of specific health conditions. This represents the market related to products and services addressing coagulation factor deficiencies. In this context, it includes biological treatments, medications, therapies, and other healthcare offerings designed for individuals with coagulation factor deficiencies. The term "increasing" signifies that the demand for biologic-based treatments for coagulation factor deficiencies is on the rise. This may be due to various factors, such as the effectiveness of biologics in treating these conditions, advancements in biotechnology, or changes in healthcare practices that prioritize biologic therapies.
In The Region, The North American Coagulation Factor Deficiency Market Holds A Significant Revenue Share.
The North American Coagulation Factor Deficiency market is expected to register a tremendous market share in terms of revenue in the near future. The market in this region may exhibit specific trends, such as increasing healthcare expenditures, a growing ageing population, changes in healthcare policies, and advancements in medical technology, all of which can impact the demand and supply of coagulation factor deficiency-related products and services.
In addition, Asia Pacific's regional market is projected to grow at a rapid rate. Each of these countries may have distinct healthcare systems, regulations, and market conditions, contributing to the diversity within the Coagulation Factor Deficiency Market in APAC. Factors Influencing the Market. Several factors can influence this market, including the prevalence of coagulation factor deficiencies, healthcare infrastructure, regulatory frameworks, awareness among healthcare professionals and the public, and the availability of treatment options, including factor VII treatment products and other therapies.
Recent Developments:
- In Oct 2022, Novo Nordisk has disclosed that Health Canada has approved a novel indication of REBINYN® (Coagulation Factor IX (Recombinant), pegylated): the management of routine prophylaxis in patients with haemophilia B who are below the age of 18. In all ages afflicted with haemophilia B (congenital factor IX deficiency or Christmas disease), one REBINYN® is recommended for routine prophylaxis to control and prevent bleeding, control and prevent bleeding episodes, and control and prevent bleeding in a perioperative setting.
- In April 2019, Grifols contributed more than 100 Bn international units (IUs) of blood clotting factor medications worldwide as a part of its long-term dedication to the World Federation of Hemophilia (WFH) in underdeveloped areas. Grifols established the Grifols Hemophilia Awareness Global Awards to bolster the worldwide effort to combat the illness.
Coagulation Factor Deficiency Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 5.50 Bn |
|
Revenue Forecast In 2031 |
USD 9.60 Bn |
|
Growth Rate CAGR |
CAGR of 7.36% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Deficiency Type, Product Type, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia |
|
Competitive Landscape |
Pfizer Inc, Grifols, Biogen, Octapharma, Baxter, Bayer, CSL Behring, Novo Nordisk, Greencross, Kedrion, BPL, Hualan Bio, RAAS, Ferring B.V., F. Hoffmann-La Roche AG, and Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
